Plasticity-Enhancing Effects of Levodopa Treatment after Stroke.
Daniela TalhadaNiklas MarklundTadeusz WielochEnida KuricKarsten RuscherPublished in: International journal of molecular sciences (2021)
Dopaminergic treatment in combination with rehabilitative training enhances long-term recovery after stroke. However, the underlying mechanisms on structural plasticity are unknown. Here, we show an increased dopaminergic innervation of the ischemic territory during the first week after stroke induced in Wistar rats subjected to transient occlusion of the middle cerebral artery (tMCAO) for 120 min. This response was also found in rats subjected to permanent focal ischemia induced by photothrombosis (PT) and mice subjected to PT or tMCAO. Dopaminergic branches were detected in the infarct core of mice and rats in both stroke models. In addition, the Nogo A pathway was significantly downregulated in rats treated with levodopa (LD) compared to vehicle-treated animals subjected to tMCAO. Specifically, the number of Nogo A positive oligodendrocytes as well as the levels of Nogo A and the Nogo A receptor were significantly downregulated in the peri-infarct area of LD-treated animals, while the number of Oligodendrocyte transcription factor 2 positive cells increased in this region after treatment. In addition, we observed lower protein levels of Growth Associated Protein 43 in the peri-infarct area compared to sham-operated animals without treatment effect. The results provide the first evidence of the plasticity-promoting actions of dopaminergic treatment following stroke.
Keyphrases
- transcription factor
- middle cerebral artery
- atrial fibrillation
- clinical trial
- cell proliferation
- parkinson disease
- metabolic syndrome
- coronary artery disease
- adipose tissue
- induced apoptosis
- newly diagnosed
- endothelial cells
- binding protein
- insulin resistance
- replacement therapy
- amino acid
- high glucose
- study protocol
- brain injury
- deep brain stimulation
- left ventricular
- cell cycle arrest
- acute coronary syndrome
- placebo controlled
- percutaneous coronary intervention
- double blind